恒生AH股溢价指数（HSAHP）目前依然在120以上，显示整体A股相比H股有20%的溢价。然而，以宁德时代（300750.SZ，03750.HK）为代表的6家公司， 却出现了H股高于A股的反常现象。 业内人士认为，在海外资金主导的港股市场，这些公司有很大部分是2025年内刚上市的次新股，H股流通量比较小；另一方面，海外投资者对细分领域行业 龙头有更多的偏好，国际市场上也很难找到相应标的，使得这些个股出现了H股价较高，或者AH股价格比较贴近的情况。 从流动性看："倒挂"次新股占比高，H股流通量小 公开信息显示，AH股价格"倒挂"的6家公司分别是：宁德时代、招商银行、恒瑞医药、潍柴动力、药明康德、美的集团；AH股价格比较贴近的则有紫金矿 业、民生银行、福耀玻璃、三一重工、海螺水泥、比亚迪等。 （原标题：6家AH股"倒挂"背后：流通股比例小，外资更爱行业龙头｜市场观察） 相比港股，A股有更低的交易成本，更好的市场流动性，A股相对H股有一定溢价，往往被投资者视为理所当然。 李泽铭称，随着IPO获配的大机构逐步退出，市场流通量增加，H股相对于A股的溢价情况有望逐步收窄，宁德时代是一个典型案例，其H股在上市半年内相 对A ...

相比港股，A股有更低的交易成本，更好的市场流动性，A股相对H股有一定溢价，往往被投资者视为理所当然。 恒生AH股溢价指数（HSAHP）目前依然在120以上，显示整体A股相比H股有20%的溢价。然而，以宁德时代（300750.SZ，03750.HK）为代表的6家公司， 却出现了H股高于A股的反常现象。 业内人士认为，在海外资金主导的港股市场，这些公司有很大部分是2025年内刚上市的次新股，H股流通量比较小；另一方面，海外投资者对细分领域行业 龙头有更多的偏好，国际市场上也很难找到相应标的，使得这些个股出现了H股价较高，或者AH股价格比较贴近的情况。 从基本面看：外资偏好行业龙头 业内人士认为，外资更倾向于投资通过市场竞争形成的行业龙头企业，这类企业在海外市场具有稀缺性，而非单纯垄断性企业。 余丰慧表示，外资在香港市场的持仓确实更倾向于具有一定垄断地位的行业龙头，这类企业在各自行业内通常占据领导地位，拥有较强的议价能力和较高的 市场份额，能够提供较为稳定的现金流和分红收益。因此，对于追求稳健回报和长期投资价值的国际投资者而言，这些行业龙头是理想的投资标的。同时， 外资选择这些股票也基于其对中国经济基本面的信心以及 ...

相比港股，A股有更低的交易成本，更好的市场流动性，A股相对H股有一定溢价，往往被投资者视为理所当然。 恒生AH股溢价指数（HSAHP）目前依然在120以上，显示整体A股相比H股有20%的溢价。然而，以宁德时代（300750.SZ，03750.HK）为代表的6家公司， 却出现了H股高于A股的反常现象。 业内人士认为，在海外资金主导的港股市场，这些公司有很大部分是2025年内刚上市的次新股，H股流通量比较小；另一方面，海外投资者对细分领域行业 龙头有更多的偏好，国际市场上也很难找到相应标的，使得这些个股出现了H股价较高，或者AH股价格比较贴近的情况。 从流动性看："倒挂"次新股占比高，H股流通量小 公开信息显示，AH股价格"倒挂"的6家公司分别是：宁德时代、招商银行、恒瑞医药、潍柴动力、药明康德、美的集团；AH股价格比较贴近的则有紫金矿 业、民生银行、福耀玻璃、三一重工、海螺水泥、比亚迪等。 光大证券国际策略师伍礼贤向第一财经分析，H股比A股有溢价的个股，存在一个现象，就是H股的市值相较A股市值更小，有些甚至是A股的市值普遍是H 股市值的几倍甚至几十倍，流动性的相对稀缺性是导致股价"倒挂"的原因之一。 红蚁资本投 ...

临近年末，市场波动加剧。中金公司指出，综合而言，投资者仍可延续"哑铃型"组合（红利+科技互联 网）作为配置底仓，并结合拥挤度动态调整组合权重，可以起到较好的对冲和平衡效果。在此基础上， 外需拉动的顺周期（铜铝等有色、化工、工程机械、甚至地产链）和创新药倒可以作为组合弹性选择， 尤其是是在一季度。 费率方面，上证180ETF指数基金管理费率为0.15%，托管费率为0.05%。 截至2025年12月2日 09:52，上证180指数(000010)成分股方面涨跌互现，传音控股(688036)领涨4.86%， 广汽集团(601238)上涨3.78%，工业富联(601138)上涨2.49%；招商轮船(601872)领跌。上证180ETF指数 基金(530280)多空胶着，最新报价1.2元。 上证180ETF指数基金紧密跟踪上证180指数，上证180指数从沪市证券中选取市值规模较大、流动性较 好的180只证券作为样本，反映上海证券市场核心上市公司证券整体表现。 上证180ETF指数基金(530280)，场外联接(平安上证180ETF联接A：023547；平安上证180ETF联接C： 023548；平安上证180ETF联接 ...

| 股份代號: | 01276 | | --- | --- | | 上市法國名稱: | 江蘇恒瑞醫藥股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 02/11/2025 - 02/12/2025 | | 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | ( 請參閱上述 * 註 | 有投票權股 (日 / 月 / 年) | | | | | | | | 份百分比 | | | | | | | | ( % ) | | CS20251201E00011 | 422,400(L) GIC Private Limited | 1101(L) | | HKD 74.9550 | 59.462.200(L) | 23.03(L)27/11/2025 | 格隆汇12月2日丨根据联交所最新权益披露资料显示，2025年11月27日，恒瑞医药(01276.HK)获GIC Pri ...

香港联交所最新资料显示，11月27日，GIC Private Limited增持恒瑞医药（600276）(01276)42.24万股， 每股作价74.955港元，总金额约为3166.1万港元。增持后最新持股数目为5946.22万股，最新持股比例为 23.03%。 ...

智通财经APP获悉，香港联交所最新资料显示，11月27日，GIC Private Limited增持恒瑞医药 (01276)42.24万股，每股作价74.955港元，总金额约为3166.1万港元。增持后最新持股数目为5946.22万 股，最新持股比例为23.03%。 ...

Investment Rating - The report does not explicitly provide an investment rating for the gynecological drug industry in China. Core Insights - The biopharmaceutical industry in China is experiencing structural optimization, valuation recovery, and confidence rebuilding, particularly in the Hong Kong market, where the 18A system supports enterprise value discovery [2][3]. - Gynecological drug companies are characterized by specialized positioning and differentiated competition, focusing on areas such as traditional Chinese medicine, innovative treatments for gynecological tumors, and hormone drugs, showcasing strong professional images and commercialization capabilities [2][3]. Summary by Sections Capital Market Performance of China's Biopharmaceutical Sector - The A-share market has shifted from a focus on scale to sustainable development, while the Hong Kong market has attracted international capital through the 18A system, leading to a gradual rebuilding of long-term confidence in the biopharmaceutical sector [3][25]. - The A-share biopharmaceutical sector has seen a total fundraising amount of 787 billion yuan from January to October 2025, with a peak of 2,451 billion yuan in 2021, indicating a transition from a capital overheating phase to a rational development phase [13][18]. - In the Hong Kong market, the total fundraising amount reached 789 billion HKD from January to October 2025, with a peak of 1,833 billion HKD in 2020, reflecting a significant improvement in the financing environment [27][28]. Market Position Assessment of Chinese Gynecological Drug Companies - The competitive landscape of gynecological drug companies is marked by a focus on specialized fields such as innovative gynecological tumor drugs and hormone treatments, with companies establishing differentiated competitive advantages [40]. - Qianjin Pharmaceutical is recognized as a leading player in the gynecological drug market, with a strong market presence in oral gynecological inflammation traditional Chinese medicine [40]. - Heng Rui Pharmaceutical is noted for its robust pipeline in gynecological tumor treatments, with eight drugs in development as of 2024 [40]. - Xianju Pharmaceutical specializes in hormone treatments, with a focus on steroid drugs, establishing a strong professional image in the gynecological field [40]. Introduction to Representative Listed Chinese Gynecological Drug Companies - Qianjin Pharmaceutical has a significant market share of 25.8% in oral gynecological inflammation traditional Chinese medicine, demonstrating strong sales performance even in challenging market conditions [45]. - Heng Rui Pharmaceutical's research and development pipeline includes multiple innovative treatments for gynecological tumors, indicating a solid commitment to this therapeutic area [52][53]. - Xianju Pharmaceutical leverages its expertise in steroid drugs to maintain a competitive edge in the gynecological drug market, with a focus on cost-effective production and high-quality formulations [58][61].

Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, and APT Medical [2][4][29] - The report also maintains an "Outperform" rating for H-Shares including Hansoh Pharmaceutical Group, 3SBio, PATEO, Akeso, and related targets such as Innovent Biologics and WuXi AppTec (H-Shares) [2][7][29] Core Insights - The report continues to recommend the innovative drug and device industry chain [1][2] - In November 2025, the pharmaceutical sector underperformed the broader market, with the SW Pharma Bio index falling by 3.6% compared to a 1.7% drop in the SHCOMP [2][10] - The premium of the pharmaceutical sector to all A-Shares is currently at a normal level of 72.6% as of the end of November 2025 [17][22] Summary by Sections A-Shares Performance - The report highlights the A-Shares that are recommended for investment, maintaining an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine and Sichuan Kelun Pharmaceutical, among others [4][5] - The report notes that the pharmaceutical sector's performance was ranked 23rd among Shenwan's first-level industries in November 2025 [10][12] H-Shares Performance - The report indicates that the H-Shares pharmaceutical sector performed in line with the market, with the Hang Seng Healthcare index down by 0.1% and the biotech sector up by 0.4% in November 2025 [2][23] - Top gainers in the H-Shares market included Laekna, Inc. (+40%) and Clover Biopharmaceuticals, Ltd. (+22%) [23] U.S. Market Performance - The U.S. pharmaceutical sector outperformed the broader market in November 2025, with the S&P Healthcare Select Sector rising by 9.1% compared to a 0.1% increase in the S&P 500 [23]

Core Insights - The Medical Health R Index (480016) closed at 7423.77 points, up 0.31%, with a trading volume of 18.443 billion yuan and a turnover rate of 0.67% [1] - Among the index constituents, 34 stocks rose while 16 fell, with Huatai Medical leading the gainers at 3.13% and Yirui Technology leading the decliners at 2.87% [1] Index Constituents Performance - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (13.66% weight) at 92.30 yuan, up 1.22%, market cap of 275.401 billion yuan [1] - Hengrui Medicine (11.00% weight) at 61.94 yuan, down 0.23%, market cap of 411.108 billion yuan [1] - Mindray Medical (7.57% weight) at 201.62 yuan, down 1.17%, market cap of 244.452 billion yuan [1] - United Imaging Healthcare (4.27% weight) at 131.30 yuan, down 1.35%, market cap of 108.212 billion yuan [1] - Other notable constituents include Pianzai Shou, Aier Eye Hospital, Kelun Pharmaceutical, and Fosun Pharma, with varying performance [1] Capital Flow Analysis - The Medical Health R Index constituents experienced a net outflow of 261 million yuan from institutional investors, while retail investors saw a net inflow of 272 million yuan [1] - Detailed capital flow for specific stocks shows: - WuXi AppTec had a net inflow of 1.15 million yuan from institutional investors, but outflows from retail and speculative investors [2] - Other stocks like Jichuan Pharmaceutical and Lijun Group also showed mixed capital flows, with some experiencing significant outflows from retail investors [2] Recent Index Adjustments - In the last 10 days, the Medical Health R Index underwent adjustments, adding four new stocks and removing one [3] - New additions include: - Sanofi Guojian, Dize Pharmaceutical, Changshan Pharmaceutical, and Kanghong Pharmaceutical, all from the biopharmaceutical sector [3]